Keyword Search
Sessions Were Renumbered as of May 19.
Legend:
CC-W = McCormick Place Convention Center, West Building, CC-N = McCormick Place Convention Center, North Building
H = Hilton Chicago, UC= Conference Chicago at University Center
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: time-to-event returned 28 record(s)
|
|
Monday, 08/01/2016
|
Sample Size and Duration of Study in Clinical Trials with Time-to-Event Endpoint
Ryunosuke Machida, Tokyo University of Science; Yosuke Fujii, Pfizer Japan; Takashi Sozu, Tokyo University of Science
|
Impact of the Violation of Independent Censoring Assumptions in Restricted Mean Survival Data Analysis for Time-to-Event Data
Eisuke Inoue, National Center for Child Health and Development
|
Review of Statistical Software for Joint Longitudinal and Time-to-Event Models
Allison Cullen, University of Michigan; Jeremy M. G. Taylor, University of Michigan; Ananda Sen, University of Michigan
|
Review of Statistical Software for Joint Longitudinal and Time-to-Event Models
Allison Cullen, University of Michigan; Jeremy M. G. Taylor, University of Michigan; Ananda Sen, University of Michigan
9:30 AM
|
Enrichment Design with Patient Augmentation for Time-to-Event Data
Yijie Zhou, AbbVie; Bo Yang, Vertex Pharmaceuticals; Lanju Zhang, AbbVie; Lu Cui, AbbVie
2:50 PM
|
|
Tuesday, 08/02/2016
|
Analysis of Clustered and Biased Survival Data with Incomplete Covariates
Hua Shen, University of Calgary
|
Innovative Bayesian Applications in Clinical Trials
Soumi Lahiri, GlaxoSmithKline; Satrajit Roychoudhury, Novartis
8:55 AM
|
Causal Effect Among the Exposed: Multiple Data Sources and Censored Outcomes
Parichoy Pal Choudhury, Johns Hopkins Bloomberg School of Public Health; Daniel Scharfstein, Johns Hopkins Bloomberg School of Public Health; Ivan Diaz, Johns Hopkins Bloomberg School of Public Health; Chris McMahan, Clemson University; Xun Luo, Johns Hopkins School of Medicine; Allan Massie, Johns Hopkins School of Medicine; Dorry Segev, Johns Hopkins School of Medicine
9:15 AM
|
Model-Assisted Estimation Using Time-to-Event Models
Benjamin Reist, U.S. Census Bureau
9:20 AM
|
Novel Imputation Methods for Binary, Time-to-Event, and Recurrent-Event Outcomes
Michael O'Kelly, Quintiles
11:35 AM
|
Recent Developments in Residual Life Inference
Jong-Hyeon Jeong, University of Pittsburgh
2:25 PM
|
|
Wednesday, 08/03/2016
|
Sample Size Planning for Survival Endpoints in Cardiovascular Clinical Trials
Ququan Liu, FDA/CDER; John Lawrence, FDA/CDER; Hsien-Ming James Hung, FDA
8:50 AM
|
Group-Sequential Clinical Trials for Comparing Two Interventions Using Two Time-to-Event Outcomes
Toshimitsu Hamasaki, National Cerebral and Cardiovascular Center; Tomoyuki Sugimoto, Hirosaki University; Koko Asakura, National Cerebral and Cardiovascular Center; Scott Evans, Harvard
10:50 AM
|
Recurrent Competing Risks, Longitudinal Markers, and Terminal Events: Modeling and Analysis with Applications in the Physical and Engineering Sciences
Edsel Aldea Pena, University of South Carolina; Piaomu Liu, Bentley University
11:05 AM
|
Modeling Events and Early Terminations to Predict
John Johnson, PPD
11:50 AM
|
Missing Data Imputation in Phase III Study with Time-to-Event Outcome
Gang Jia, Merck; Paul DeLucca, Merck; Steven Bird, Merck; Bruce Binkowitz, Merck; Weichung J. Shih, Rutgers University
2:05 PM
|
An Extended Kaplan-Meier Estimator for Time-to-Event Data with Informative Censoring
Misun Yu Lee, Astellas Pharma; Wei Li, Astellas Pharma
2:35 PM
|
Considerations for Analysis of Time-to-Event Outcomes Measured with Error
Eric Oh, University of Pennsylvania; Pamela A. Shaw, University of Pennsylvania
3:20 PM
|
Improved Designs and Analyses of Safety and Efficacy in Immuno-Oncology
Bo Huang, Pfizer; Margarida Geraldes, Pfizer
3:25 PM
|
|
Thursday, 08/04/2016
|
Attributable Excess Time Function for Censored Time-to-Event
Yixin Wang, Fred Hutchinson Cancer Research Center; Ying Qing Chen, Fred Hutchinson Cancer Research Center
8:35 AM
|
Statistical Testing in the Presence of Nonproportional Hazards
Amarjot Kaur, Merck; Yabing Mai, Merck Research Laboratories; Ziliang Li, MRL; Xia Xu, MRL; Wen-Chi Wu, MRL
8:50 AM
|
Issues of Conventional Meta-Analysis for Time-to-Event Outcomes Using Reported Hazard Ratios or Relative Risks from Independent Studies
Hajime Uno, Dana-Farber Cancer Institute; Masayuki Kaneko, Kitasato University
10:55 AM
|
Estimating the Optimal Treatment Regime for Time-to-Event Data
Min Zhang, University of Michigan; Baqun Zhang, Renmin University of China
11:15 AM
|
How to Control for Unmeasured Confounding in an Observational Time-to-Event Study with Exposure Incidence Information: The Treatment Choice Cox Model
James Troendle, National Institutes of Health; Zhiwei Zhang, FDA/CDRH; Eric Leifer, National Heart, Lung, and Blood Institute; Song Yang, National Heart, Lung, and Blood Institute; Michael Sklar, University of Pennsylvania; Heather Jerry, Nebraska Department of Health and Human Services
11:35 AM
|
Use of Co-Data in Clinical Trials with Time-to-Event Endpoint
Satrajit Roychoudhury, Novartis
11:35 AM
|
Joint Modeling of Time-to-Event and Laboratory Test Data
Kao-Tai Tsai
11:35 AM
|
|
|
